Vytrus Biotech joins BME Growth and its share value rises by 25% on its stock market debut

March 15, 2022
Vytrus made its debut this Tuesday, March 15, and it closed its first trading day on BME Growth (SME stock market) with an increase in its market value of more than 25%

We started our debut on the BME Growth market with a 19.77% rise after the traditional bell ringing celebrated in an exciting event at the Barcelona Stock Exchange, being the second company to be released on the SME market in 2022. At the close of our first day, Vytrus’ valuation was up 25.58%, with a price of €2.16 per share.

The Board of Directors of BME Growth recently approved the listing of Vytrus Biotech on the BME Growth market, once all the documentation submitted by the company had been analyzed and studied and the favorable evaluation report of the Market Coordination and Incorporations Committee had been issued. The value of our share has debuted on the stock exchange at a price of 1.72 euros, which represents an initial valuation of the company of 12.24 million euros.

We made our debut on the BME Growth in the form of a listing without placement, under the trading code “VYT”, with GVC Gaesco Valores as Registered Advisor and Liquidity Provider, and Garrigues and IMB Grup as legal advisors.

Founded more than 12 years ago by Albert Jané, biotechnologist and biochemist and Master in Pharmaceutical Sciences, and Òscar Expósito, biologist and PhD in Plant Biotechnology, and current CEOs, Vytrus has increased by 65% its turnover during the financial year 2021 to 2.8 million euros compared to 2020, which represents an increase in sales of 133% in the two years of pandemic and a double-digit annual increase, in the trend of increase of the last 5 years. We have also managed in 2021 to increase EBITDA by 91% to €1.13 million compared to 2020 and to multiply by more than 5 the EBITDA we obtained in 2019.

The fact of Vytrus being listed on BME Growth, the SME stock market, provides us with a liquidity mechanism and objective valuation of Vytrus shares as a reference for potential future corporate operations. On the other hand, being a listed company helps us to increase our brand image, transparency, and solvency, thus strengthening our relationship with clients, investors, suppliers, and financiers.
Albert Jané
CEO, COO, and cofounder
65% of sales - exports to more than 30 countries.

Pending the annual audit, we estimate that we could close 2021 with the best results in its history, where 65% of our sales are the result of exports to more than 30 countries. In Vytrus we have closed 2021 with a team of almost 30 qualified workers, and with facilities of 1,400 m2 in Terrassa (Barcelona) where we research, develop, produce, and market active ingredients of high added value for the cosmetics industry and the health sector.

More information is available in the investor area of the website.